Recursion aligns with FDA on registrational Phase 3 design for FAP candidate REC-4881
What's the deal? Recursion, the AI-enabled drug discovery company, announced on 18 November 2026 that it has aligned with the US FDA on the design of its registrational Phase 3 trial of REC-4881, an investigational oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP), a rare inherited condition that causes hundreds of colorectal polyps and a near-certain risk of colorectal cancer. The company reported positive Phase 2 data in November 2026 in which 87% of patients reduced their polyp burden, with a median reduction of 47%, durable even after stopping treatment.
Why it matters: FAP patients typically face preventive colectomy (removal of the colon) in early adulthood because no approved therapy reduces polyp burden. FDA alignment on a registrational Phase 3 design — the last major step before a pivotal study — puts REC-4881 on a defined path toward potential approval and a first-ever drug option for FAP, advancing Recursion's first wholly owned candidate into late-stage development.
Read more: BioSpace, 18 November 2026